Phase II Trial Evaluating the Combination of Gemcitabine, Trastuzumab and Erlotinib as First-line Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Disease control rate according to RECIST criteria of the Gemcitabine, Trastuzumab and Erlotinib combination.
The tumor evaluation will be based on: Clinical examination TAP CT-scan or MRI Tumor marker dosage (CEA and CA 19-9)
Every 8 weeks and at the treatment completion
No
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
GATE 1
NCT01204372
June 2010
Name | Location |
---|